29th Apr 2008 07:01
Stem Cell Sciences plc29 April 2008 Press Release For Immediate Release 29th April 2008 Stem Cell Sciences plc Grant of Options Stem Cell Sciences plc, the global biotechnology company focused on thecommercialisation of stem cells and stem cell technologies in research andcell-based therapies, announces that on 25th April 2008, Dr Alastair J Riddell,Chief Executive Officer, was granted options to acquire 162,500 new OrdinaryShares in the Company at a price of 15 pence per share. The options vest immediately following the execution of the successfulrestructure of the Company and the strike price is based upon the averagetrading price over the three days prior to the grant date of 25th April 2008. - Ends- For further information, please contact: Stem Cell Sciences plc (United Kingdom)Giorgio Reggiani, Company Secretary +44 (0)1223 499160 Notes to EditorsStem Cell Sciences plc (SCS, AIM:STEM, ASX:STC) is a leading provider of cellsand cell culture media to the burgeoning stem cell research market. Thesuccessful application of stem cells in both research and clinical applicationsis reliant on the reproducible supply of pure, fully characterised stem cellsand stem cell-derived specialised cells such as nerves and muscle. By providingthese products, to the life sciences industry and academia for use in basicresearch and drug discovery, Stem Cell Sciences has multiple potential revenuestreams. Stem Cell Sciences has multiple industry collaborations, including MilliporeCorporation for the marketing and distribution of HEScGROTM, its serum freemedia for the growth of human embryonic stem cells and Merck & Co for the use ofmouse neural stem cell technology for research applications. It recentlyannounced deals with a major pharmaceutical company in the field of diabetesresearch and with the Myelin Repair Foundation in the USA in neurologicalresearch. To access cutting edge technologies on a rapid and on-going basis, Stem CellSciences has built an exceptional network of highly interactive collaborationswith academic centres of excellence in the stem cell field. These collaborationshave been the source of our founding technologies and continue to provide anexpanding pipeline of products and intellectual property that are central to theCompany's strategy and success. For further information on the company pleasevisit: www.stemcellsciences.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SThree